A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Zhu, Ji ^a,b   Gu, Weilie ^a,b   Lian, Peng ^a,b   Sheng, Weiqi ^a,b   Cai, Gang ^a,b   Shi, Debing ^a,b   Cai, Sanjun ^a,b   Zhang, Zhen ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Intensity modulated radiation therapy; Neoadjuvant chemoradiotherapy; Rectal cancer

Indexed keywords

CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; PLATINUM COMPLEX;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ANUS SPHINCTER; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; DIARRHEA; DISEASE FREE SURVIVAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE INFECTION; RADIATION DERMATITIS; RADIATION DOSE; RECTUM CARCINOMA; SKIN TOXICITY; TREATMENT RESPONSE; ABDOMINAL SURGERY; ADENOCARCINOMA; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; CHEMORADIOTHERAPY; CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RECTAL NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RADIOTHERAPY, INTENSITY-MODULATED; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84878232645     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-130     Document Type: Article

References (20)

1. Collette L, Bosset JF, den Dulk M. Patients with curative resection of cT3-4 rectal cancer after preoperativeradiotherapy or radiochemotherapy: does anybody benefit from adjuvantfluorouracil-based chemotherapy? A trial of the European Organisation forResearch and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007, 25(28):4379-4386. 10.1200/JCO.2007.11.9685, 17906203.
2. Capirci C, Valentini V, Cionini L. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008, 72(1):99-107. 10.1016/j.ijrobp.2007.12.019, 18407433.
3. Hartley A, Ho KF, McConkey C, Geh JI. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. Br J Radiol 2005, 78(934):934-938. 10.1259/bjr/86650067, 16177017.
4. Gerard JP, Azria D, Gourgou-Bourgade S. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010, 28(10):1638-1644. 10.1200/JCO.2009.25.8376, 20194850.
5. Rodel C, Liersch T, Becker H. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012, 13(7):679-687. 10.1016/S1470-2045(12)70187-0, 22627104.
6. Aschele C, Cionini L, Lonardi S. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011, 29(20):2773-2780. 10.1200/JCO.2010.34.4911, 21606427.
7. Roh GAY MS, O'Connell MJ. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011, 29(suppl; abstr 3503). An abstract of ASCO 2011, no formal published paper now.
8. Bakst RL, Lee N, Pfister DG. Hypofractionated dose-painting intensity modulated radiation therapy withchemotherapy for nasopharyngeal carcinoma: a prospective trial. Int J Radiat Oncol Biol Phys 2011, 80(1):148-153. 10.1016/j.ijrobp.2010.01.026, 2952060, 20605352.
9. Kim K, Wu HG, Kim HJ. Intensity-modulated radiation therapy with simultaneous integrated boosttechnique following neoadjuvant chemotherapy for locoregionally advancednasopharyngeal carcinoma. Head Neck 2009, 31(9):1121-1128. 10.1002/hed.21076, 19340863.
10. Williams MV, Denekamp J, Fowler JF. A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys 1985, 11(1):87-96. 10.1016/0360-3016(85)90366-9, 3881377.
11. Hodapp N. The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT). Strahlenther Onkol 2012, 188(1):97-99. 10.1007/s00066-011-0015-x, 22234506.
12. Withers HR, Thames HD, Peters LJ. A new isoeffect curve for change in dose per fraction. Radiother Oncol 1983, 1(2):187-191. 10.1016/S0167-8140(83)80021-8, 6680223.
13. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986, 2(8514):996-999.
14. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997, 12(1):19-23. 10.1007/s003840050072, 9112145.
15. Mok H, Crane CH, Palmer MB. Intensity modulated radiation therapy (IMRT): differences in target volumes andimprovement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol 2011, 6:63. 10.1186/1748-717X-6-63, 3121606, 21651775.
16. Wolff HA, Wagner DM, Conradi LC. Irradiation with protons for the individualized treatment of patients with locally advanced rectal cancer: a planning study with clinical implications. Radiother Oncol 2012, 102(1):30-37. 10.1016/j.radonc.2011.10.018, 22112780.
17. Guerrero UMT, Henrys AJ, Adams EJ. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys 2006, 65(3):907-916. 10.1016/j.ijrobp.2005.12.056, 16751073.
18. Fernandez-Martos C, Pericay C, Aparicio J. Phase II, randomized study of concomitant chemoradiotherapy followed by surgeryand adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonanceimaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010, 28(5):859-865. 10.1200/JCO.2009.25.8541, 20065174.
19. Park IJ, You YN, Agarwal A. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 2012, 30(15):1770-1776. 10.1200/JCO.2011.39.7901, 3383178, 22493423.
20. Rodel C, Martus P, Papadoupolos T. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23(34):8688-8696. 10.1200/JCO.2005.02.1329, 16246976.